News
Alphamab’s bispecific ADC enters the IND pipeline with promise. JSKN022 is an innovative bispecific ADC developed in-house with Alphamab's proprietary glycan-specific conjugation platform. The ...
Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN022, an independently developed innovative bispecific antibody-drug conjugate (ADC) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback